Mice with orthotopic syngenetic PDAC tumors who received RFA in combination with gemcitabine, anti-PD-1, and anti-CTLA-4 were found to have increased tumor antigen presentation and T cell recruitment and activation as demonstrated by whole RNA-sequencing and spatial transcriptomics [105]. The gene discussed is CTLA4; the disease is neoplasm.